Maximize your thought leadership

IntegrateRNA Launches Custom Aminoacyl-tRNA Synthesis Service to Advance Protein Engineering Research

By FisherVista

TL;DR

Creative Biogene's IntegrateRNA offers a competitive edge by enabling customized protein synthesis for enhanced drug discovery and industrial enzyme development.

The service uses an enzyme-based in vitro system to covalently link amino acids to tRNA molecules, supporting non-canonical amino acid incorporation.

This technology accelerates therapeutic protein development, potentially leading to next-generation biopharmaceuticals that improve human health outcomes.

Scientists can now engineer proteins with non-standard amino acids, creating unique properties impossible through natural processes alone.

Found this article helpful?

Share it with your network and spread the knowledge!

IntegrateRNA Launches Custom Aminoacyl-tRNA Synthesis Service to Advance Protein Engineering Research

IntegrateRNA, the R&D division of Creative Biogene, has launched a new Aminoacyl-tRNA In Vitro Synthesis Service designed to support protein synthesis research by enabling the generation of customized aminoacylated tRNAs. These molecules are essential for robust protein translation in in vitro systems, allowing for more accurate and scalable synthesis of proteins containing non-canonical amino acids.

The service utilizes an enzyme-based process that mimics natural cellular translation, covalently linking amino acids to transfer RNA molecules through a robust in vitro translation system. This technology supports the inclusion of non-canonical or modified amino acids, significantly expanding the design possibilities for researchers. Scientists can now design and produce custom proteins with enhanced stability, activity, or specificity, with potential applications in developing new therapeutics and industrial enzymes.

Marcia Brady, Head of Technology at Creative Biogene, emphasized the transformative nature of this development, stating that synthesizing proteins with non-canonical amino acids opens new possibilities for designing proteins with specific properties and could significantly accelerate biotechnology development. The service is expected to find applications across pharmaceutical R&D, protein engineering, and novel biologics development, particularly in creating protein variants with unique properties not achievable through natural processes alone.

Future plans for the platform include supporting an even broader array of amino acid modifications and scaling production to industrial levels. These advancements could substantially impact synthetic biology and therapeutic protein development, potentially leading to next-generation biopharmaceuticals and engineered enzymes. The service represents a significant step forward in protein engineering capabilities, offering researchers enhanced tools for drug discovery and biotechnology innovation. More information about the company's services can be found at https://www.creative-biogene.com.

Curated from 24-7 Press Release

blockchain registration record for this content
FisherVista

FisherVista

@fishervista